Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple-dose subcutaneous donidalorsen trial in healthy adults
jRCT2051240291Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2025
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of donidalorsen in hereditary angioedema (HAE) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Plasma donidalorsen concentration, Plasma pharmacokinetic parameters and 11 more. Started May 2025; status: completed.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2051240291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240291.